Multicenter, USA - 03 Oct `19Incyte: Ruxolitinib cream (TRuE-V2)

Official Title: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

In Brief: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Description: Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.

Details: For a plain language details check Incyte announcement or download pdf of a scientific presentation from UMass.

Ages Eligible: 12 Years and older 

Start Date: October 3, 2019

Completion Date (estimated): November 30, 2021

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT04057573
Other Study ID Numbers: INCB 18424-307 

Locations

  • Center For Dermatology and Plastic Surgery: Scottsdale, Arizona, United States, 85260
  • Burke Pharmaceutical Research: Hot Springs, Arkansas, United States, 71913
  • Marvel Clinical Research: Huntington Beach, California, United States, 92647
  • Rady Children's Hospital: San Diego, California, United States, 92123
  • Clinical Research Center of Connecticut: Danbury, Connecticut, United States, 06810
  • Harmony Medical Research Institute: Hialeah, Florida, United States, 33016
  • San Marcus Research Clinic: Miami Lakes, Florida, United States, 33014
  • ForCare Medical Center: Tampa, Florida, United States, 33613
  • Metabolic Research Institute: West Palm Beach, Florida, United States, 33401
  • Northwestern University, Chicago, Illinois, United States, 60611
  • Great Lakes Research Group: Bay City, Michigan, United States, 48706
  • Washington University in St Louis: Saint Louis, Missouri, United States, 63141
  • SUNY Downstate Medical Center: Brooklyn, New York, United States, 11203
  • Forest Hills Dermatology Group: Forest Hills, New York, United States, 11375
  • Buka Dermatology: New York, New York, United States, 10012
  • M3 Wake Research: Raleigh, North Carolina, United States, 27612
  • Wake Forest University Health Sciences: Winston-Salem, North Carolina, United States, 27157
  • KGL Skin Study Center: Broomall, Pennsylvania, United States, 19008
  • Dermatology Associates of Plymouth Meeting: PC Plymouth Meeting, Pennsylvania, United States, 19462
  • Palmetto Clinical Trial Services: Anderson, South Carolina, United States, 29621
  • International Clinical Research-Tennessee: Murfreesboro, Tennessee, United States, 37130
  • Progressive Clinical Research - San Antonio: San Antonio, Texas, United States, 78213
  • Dermatology Clinical Research Center of San Antonio; San Antonio, Texas, United States, 78229
  • Dermatology Specialists of Spokane: Spokane, Washington, United States, 99202

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • Will it spread?

    Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...